The findings suggested that the molecular trigger of psoriasis relapse may not completely rely on the CD28-CD80/CD86 costimulation pathway and/or may be dependent on compensatory T-cell activation pathways in the presence of abatacept. This evidence concerns the gene CD86 and psoriasis.